Medicare Part D Plans Shrinking as Medicare Advantage Enrollment Grows

The Medicare Part D prescription drug plan market is evolving significantly due to rising enrollment in Medicare Advantage plans, regulatory changes, and cost pressures. Since 2020, there has been a notable shift with a declining percentage of enrollees choosing stand-alone Part D plans under original Medicare, dropping from 53% to 42% by 2025 as Medicare Advantage with integrated drug coverage grows. The number of stand-alone Part D plans is also decreasing substantially, forecasted to fall nearly 25% from 464 plans in 2025 to 360 in 2026 nationwide. Despite this reduction, beneficiaries still retain multiple options, with 8 to 12 stand-alone plans typically available in each state during the 2026 open enrollment period. Concurrently, Medicare Advantage enrollees can select from about 32 plans including drug coverage, offering broader choices although slightly fewer than the previous year. Market dynamics strongly favor Medicare Advantage due to its funding structure and the ability to offer low or no premiums for drug coverage, supported by government rebates. Over half of Medicare beneficiaries now receive prescription coverage through Medicare Advantage, which combines medical and drug benefits. In contrast, stand-alone plan sponsors face increasing financial challenges from a 2022 law that caps beneficiaries' out-of-pocket costs and shifts more expenses onto insurers and pharmaceutical companies, impacting premiums and plan availability. The number of premium-free stand-alone plans for low-income enrollees receiving Extra Help is also declining, reducing from 126 in 2024 to 88 plans in 2026, the fewest historically. Premium cost trends show that the average stand-alone Part D monthly premium is expected to be $34.50 in 2026, down nearly 10% from 2025, while Medicare Advantage plans' average premium will be around $11.50 after rebates. Many stand-alone plans still impose deductibles and higher cost-sharing compared to Medicare Advantage, which uses rebates to mitigate these costs, enhancing its competitiveness. This divergence affects beneficiaries' cost structure and choice dynamics. Medicare Advantage's ability to offer integrated coverage with favorable premium structures incentivizes enrollment, thus reducing the stand-alone plan market share. Insurers commonly adjust cost controls through formularies, utilization management, and network designs across both product types to manage expenses. Beneficiaries are encouraged to review coverage changes annually due to plan variability and regional differences. Tools such as the Medicare Plan Finder and assistance programs like State Health Insurance Assistance Programs (SHIP) provide beneficiaries with resources to compare plan options effectively. AARP continues to monitor and advocate for balanced policies that support both traditional Medicare and Medicare Advantage, emphasizing the importance of robust consumer choice and fair payment systems. Additionally, potential conflicts of interest in using Medicare brokers and agents are noted, as their compensation models may affect impartiality in plan recommendations. This evolving landscape reflects ongoing adjustments in Medicare drug coverage driven by regulatory reform, market competition, and cost containment strategies, with implications for beneficiary access, insurer participation, and federal budget impact. Stakeholders should maintain awareness of these shifts to navigate enrollment decisions and policy developments.